Cyclodinone tablets, no. 30

Menstrual irregularities, premenstrual syndrome, mastodynia.

Before using the drug, you should consult your doctor.

Take 1 tablet orally 1 time per day in the morning, without chewing, drinking a sufficient amount of 100-200 ml of water. The duration of treatment is at least 3 months (without interruption during menstruation). Use of the drug for more than 3 months should be discussed with your doctor. If the symptoms of the disease persist against the background of the use of the drug, you should consult a doctor. If, after the completion of treatment, complaints reappear, it is necessary to consult a doctor.

There are no data on recommended doses for renal or hepatic impairment.

The drug should not be used to treat children and adolescents under the age of 18 years.

Active ingredient:

Common barnacle * fruit dry extract (7-11: 1, extractant - ethanol 70% v / v) - 4.00 mg

Excipients: povidone K 30, colloidal silicon dioxide, potato starch, lactose monohydrate, microcrystalline cellulose, magnesium stearate, talc, titanium dioxide (E 171), iron dye yellow oxide (E 172), indigo carmine aluminum lacquer (E 132), macrogol 6000, ammonium methacrylate copolymer (type A)

* Latin name - Vitex agnus-castus L.

Individual hypersensitivity to the components of the drug, lactose intolerance, lactase deficiency, glucose-galactose malabsorption (due to the content of lactose in the drug), breast cancer, pituitary tumors, age up to 18 years (there are no data on the effectiveness and safety of the drug in this age group ); pregnancy and breastfeeding period.

Dosage form

film-coated tablets

Manufacturer

Bionorica SE, Kerschensteinerstrasse 11-15, 92318, Neumarkt, Germany

Composition (for 1 tablet):

Active ingredient:

Common barnacle * fruit dry extract (7-11: 1, extractant - ethanol 70% v / v) - 4.00 mg

Excipients: povidone K 30, colloidal silicon dioxide, potato starch, lactose monohydrate, microcrystalline cellulose, magnesium stearate, talc, titanium dioxide (E 171), iron dye yellow oxide (E 172), indigo carmine aluminum lacquer (E 132), macrogol 6000, ammonium methacrylate copolymer (type A)

* Latin name - Vitex agnus-castus L.

Description

Round biconvex film-coated tablets of greenish-blue color with a matte surface.

Pharmacotherapeutic group

Preparations for the treatment of gynecological diseases

Pharmacological properties

The components of the drug have a normalizing effect on the concentration of sex hormones.

The main active ingredient of the drug is common twig. The dopaminergic effects of the drug, causing a decrease in prolactin production, eliminate hyperprolactinemia. An increased concentration of prolactin disrupts the secretion of gonadotropins, as a result of which there may be disturbances in follicular maturation, ovulation and the formation of a corpus luteum, which further leads to an imbalance between estradiol and progesterone and can cause menstrual irregularities, as well as mastodynia. Unlike estrogens and other hormones, prolactin also has a direct stimulating effect on the proliferative processes in the mammary glands, enhancing the formation of connective tissue and causing the expansion of the milk ducts. A decrease in the concentration of prolactin leads to the reverse development of pathological processes in the mammary glands and relieves pain.Rhythmic production and normalization of the ratio of gonadotropic hormones leads to the normalization of the second phase of the menstrual cycle.

Indications for use

Menstrual irregularities, premenstrual syndrome, mastodynia.

Before using the drug, you should consult your doctor.

Contraindications

Individual hypersensitivity to the components of the drug, lactose intolerance, lactase deficiency, glucose-galactose malabsorption (due to the content of lactose in the drug), breast cancer, pituitary tumors, age up to 18 years (there are no data on the effectiveness and safety of the drug in this age group ); pregnancy and breastfeeding period.

Carefully

Precautions must be taken if patients have a history of estrogen-dependent malignant neoplasms and diseases of the pituitary gland. Before using the drug, you should consult your doctor.

Application during pregnancy and lactation

The drug is not used during pregnancy and during breastfeeding.

With an increase in the regularity of the menstrual cycle while taking the drug, the likelihood of pregnancy increases. When pregnancy occurs, the drug should be discontinued.

Method of administration and dosage

Take 1 tablet orally 1 time per day in the morning, without chewing, drinking a sufficient amount of 100-200 ml of water. The duration of treatment is at least 3 months (without interruption during menstruation). Use of the drug for more than 3 months should be discussed with your doctor. If the symptoms of the disease persist against the background of the use of the drug, you should consult a doctor. If, after the completion of treatment, complaints reappear, it is necessary to consult a doctor.

There are no data on recommended doses for renal or hepatic impairment.

The drug should not be used to treat children and adolescents under the age of 18 years.

Side effects

Severe allergic reactions with facial edema, shortness of breath and dysphagia are possible. Allergic skin reactions (rash, urticaria), gastrointestinal disorders (epigastric pain, nausea), headache, dizziness, acne, menstrual irregularities may occur. The frequency of adverse reactions is unknown, i.e. cannot be estimated based on the available data. If the adverse reactions described above or other adverse reactions not specified in the instructions appear, the drug should be discontinued and consult a doctor.

Overdose

Overdose cases have not been registered. In case of overdose, it is possible to increase the severity of dose-dependent side effects. Treatment is symptomatic.

Interaction with other medicinal products

A mutual decrease in effectiveness is possible while taking dopamine receptor antagonists, as well as interaction with dopamine receptor agonists, estrogens and antiestrogens. When taking these drugs, you should consult your doctor before you start taking CyclodinoneЃ.

Interaction with other drugs is currently unknown.

special instructions

Indication for patients with diabetes mellitus: the carbohydrates included in 1 tablet of the drug are less than 0.03 'bread units' (XE).

If you have a history of malignant estrogen-dependent tumors or a history of pituitary diseases, a doctor's consultation is required.

Consideration should be given to the possibility of masking the clinical manifestations of a prolactin-secreting pituitary tumor while taking the drug.

The list of conditions requiring medical advice: if you feel tension and swelling of the mammary glands and / or weakness, depression, as well as in case of menstrual irregularities, you should consult a doctor for additional examination.

In order to monitor the effectiveness of the treatment, a monthly consultation with a doctor is recommended.

Influence on the ability to drive vehicles, mechanisms

When used in recommended doses, the drug does not affect the ability to perform potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions (driving, working with moving mechanisms, the work of a dispatcher and an operator).

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ? C.

Keep out of the reach of children!